Search

Your search keyword '"Schumacher, Ton"' showing total 1,373 results

Search Constraints

Start Over You searched for: Author "Schumacher, Ton" Remove constraint Author: "Schumacher, Ton"
1,373 results on '"Schumacher, Ton"'

Search Results

1. Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy

3. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

8. Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

9. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response

10. PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial

11. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

12. B cells and tertiary lymphoid structures promote immunotherapy response

13. An adverse tumor-protective effect of IDO1 inhibition

14. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer

15. Non-clinical evaluation of NT-112, an autologous T cell product engineered to express an HLA-C*08:02-restricted TCR targeting KRAS G12D and resistant to TGF-b inhibition.

18. T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes

19. The Human Cell Atlas.

20. Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening

21. CD8-targeted IL2 unleashes tumor-specific immunity in human cancer tissue by reviving the dysfunctional T cell pool

22. IL-2 targeted to CD8+ T cells promotes robust effector T cell responses and potent antitumor immunity

25. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer

26. DNA damage induces p53-independent apoptosis through ribosome stalling

29. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

30. The “cancer immunogram”

31. CANCER IMMUNOLOGY. The "cancer immunogram".

32. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

33. Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features

34. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma

36. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

39. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

41. DNA damage induces p53-independent apoptosis through ribosome stalling.

42. 1006 High doses of MHC-II neoantigens in peptide cancer vaccines induce tumor-specific inhibitory cytolytic CD4+T cells

43. CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1

45. Defining ‘T cell exhaustion’

46. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis

48. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Catalog

Books, media, physical & digital resources